norvancomycin: glycopeptide; adverse reactions tend to occur in older patients, those who use other antibiotic concomitantly or those who receive this agent longer than 14 days [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10419027 |
| CHEMBL ID | 4303504 |
| MeSH ID | M0499199 |
| Synonym |
|---|
| norvancomycin |
| J985.647A , |
| NCGC00484083-01 |
| CHEMBL4303504 |
| Q27274780 |
| antibiotic a-51568a |
| desmethylvancomycin |
| antibiotic a 51568a |
| norvancomycin [who-dd] |
| 56-demethylvancomycin |
Norvancomycin is an antibiotic that has been approved for the treatment of infections caused by antibiotic-resistant Gram-positive bacteria. It has been used in China for more than a decade.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Norvancomycin is an antibiotic that has been approved for the treatment of infections caused by antibiotic-resistant Gram-positive bacteria and has been used in China for more than a decade. " | ( Pharmacokinetics and cerebrospinal fluid penetration of norvancomycin in Chinese adult patients. He, S; Li, J; Lu, C; Yang, Z, 2017) | 2.14 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Norvancomycin has been widely used in clinic to treat against MRSA (Methicillin-resistant Staphylococcus aureus) and MRSE (Methicillin-resistant Staphylococcus epidermidis) infections in China. " | ( Comparative genomics and transcriptomics analyses provide insights into the high yield and regulatory mechanism of Norvancomycin biosynthesis in Amycolatopsis orientalis NCPC 2-48. Hong, B; Jiang, Z; Lei, X; Li, X; Si, S; Wang, L; Zhang, C; Zhang, X; Zhao, Y; Zheng, Z, 2021) | 2.27 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic parameters were calculated by the 3P87 pharmacokinetic program." | ( Study on pharmacokinetics and tissue distribution of norvancomycin in rats by CE with electrochemical detection. Fang, Y; Hu, Q; Shi, G; Wang, A; Wang, X; Wu, F; Zhou, T, 2006) | 0.58 |
| " The best model was a two-compartment pharmacokinetic model with exponential inter-individual error and an additive residual error statistic model." | ( Population pharmacokinetic and pharmacodynamic modeling of norvancomycin. Cao, G; Rui, J; Shi, Y; Wu, J; Yu, J; Zhang, J; Zhang, Y, 2008) | 0.59 |
The fast analysis method was adopted to detect residues of vancomycin and norvan comycin in milk. It was implemented on a chromatographic system containing online solid-phase extraction (SPE) device and high-resolution mass spectrometer (HRMS)
| Excerpt | Reference | Relevance |
|---|---|---|
| "A fast analysis method, which was adopted to detect residues of vancomycin and norvancomycin in milk, was implemented on a chromatographic system containing online solid-phase extraction (SPE) device that combined with high-resolution mass spectrometer (HRMS)." | ( Determination of Vancomycin and Norvancomycin Residues in Milk by Automated Online Solid-Phase Extraction Combined With Liquid Chromatography-High Resolution Mass Spectrometry. Ai, LF; Chen, MN; Liang, SX; Wang, H; Wang, HP; Zhang, Y, 2022) | 1.23 |
| "The method for detecting vancomycin and norvancomycin residues in milk by online SPE combined with LC-HRMS." | ( Determination of Vancomycin and Norvancomycin Residues in Milk by Automated Online Solid-Phase Extraction Combined With Liquid Chromatography-High Resolution Mass Spectrometry. Ai, LF; Chen, MN; Liang, SX; Wang, H; Wang, HP; Zhang, Y, 2022) | 1.27 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
The aim of the study was to investigate the pharmacokinetics and CSF penetration of norvancomycin in meningitis and non-meningitis patients. The proposed simulation may be useful to clinicians for norvan comycin dosing in this specific population.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Increasing the intravenous dosage or frequency carries the risk of systemic adverse reactions or infections in other parts of the body." | ( Preliminary exploration of the development of a collagenous artificial dura mater for sustained antibiotic release. Dong, H; Kang, CG; Lin, C; Wang, H; Ye, X; Zhao, YL, 2013) | 0.39 |
| "The minimum inhibitory concentrations (MICs) of vancomycin and norvancomycin for half of the isolates decreased below the susceptibility break point, and the MIC of linezolid for one isolate was decreased to the blood and epithelial lining fluid concentration using the current dosing regimen." | ( Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii. Bai, Y; Di, X; Liu, B; Liu, Y; Wang, J; Wang, R; Zhang, X, 2014) | 0.64 |
| " The aims of the study were (i) to investigate the pharmacokinetics and CSF penetration of norvancomycin in meningitis and non-meningitis patients and (ii) to recommend favourable dosing regimens in meningitis patients." | ( Pharmacokinetics and cerebrospinal fluid penetration of norvancomycin in Chinese adult patients. He, S; Li, J; Lu, C; Yang, Z, 2017) | 0.92 |
| " A dosage regimen table was created for specific patient populations with different weights and drainage amounts to facilitate clinical application." | ( Factors Influencing Norvancomycin Concentration in Plasma and Cerebrospinal Fluid in Patients After Craniotomy and Dosing Guideline: A Population Approach. Li, X; Sun, S; Wang, Q; Wu, Y; Zhao, Z, 2018) | 0.8 |
| " The proposed simulation may be useful to clinicians for norvancomycin dosing in this specific population with normal kidney function." | ( Factors Influencing Norvancomycin Concentration in Plasma and Cerebrospinal Fluid in Patients After Craniotomy and Dosing Guideline: A Population Approach. Li, X; Sun, S; Wang, Q; Wu, Y; Zhao, Z, 2018) | 1.05 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1704230 | Antibacterial activity against Vancomycin-resistant enterococcus 1 incubated for 16 hrs by agar dilution method | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | 1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). |
| AID1704231 | Antibacterial activity against Vancomycin-resistant enterococcus 2 incubated for 16 hrs by agar dilution method | 2020 | European journal of medicinal chemistry, Nov-15, Volume: 206 | 1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (21.43) | 29.6817 |
| 2010's | 18 (42.86) | 24.3611 |
| 2020's | 15 (35.71) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (4.76%) | 5.53% |
| Reviews | 1 (2.38%) | 6.00% |
| Case Studies | 1 (2.38%) | 4.05% |
| Observational | 1 (2.38%) | 0.25% |
| Other | 37 (88.10%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||